Evidence map›Paper›PMID 25047537›Full record

ArticlePloS one2014

VapC from the leptospiral VapBC toxin-antitoxin module displays ribonuclease activity on the initiator tRNA.

Alexandre P Y Lopes, Luana M Lopes, Tatiana R Fraga, Rosa M Chura-Chambi, André L Sanson, Elisabeth Cheng, Erika Nakajima, Ligia Morganti, Elizabeth A L Martins

Open access · goldAbstract read
In one paragraph

Article in PloS one, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 28 papers.

0numbers the graph read from it
0cells of the map it votes in
28citing papers in PubMed
4.3field-weighted citation impact, top 5% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

28 citing papers in PubMed, 44 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Serovar-specific genomic features ofFrontiers in molecular biosciences · 2025
    Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Review
  14. Microorganisms · 2019
    Article
  15. Review
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 3 institutions in 1 country.

Alexandre P Y LopesCentro de Biotecnologia, Instituto Butantan, São Paulo, São Paulo, Brazil.
Luana M LopesCentro de Biotecnologia, Instituto Butantan, São Paulo, São Paulo, Brazil.
Tatiana R FragaCentro de Biotecnologia, Instituto Butantan, São Paulo, São Paulo, Brazil.
Rosa M Chura-ChambiCentro de Biotecnologia, Instituto de Pesquisas Energéticas e Nucleares, Comissão Nacional de Energia Nuclear, São Paulo, São Paulo, Brazil.
André L SansonCentro de Biotecnologia, Instituto Butantan, São Paulo, São Paulo, Brazil.
Elisabeth ChengCentro de Biotecnologia, Instituto Butantan, São Paulo, São Paulo, Brazil.
Erika NakajimaCentro de Biotecnologia, Instituto Butantan, São Paulo, São Paulo, Brazil.
Ligia MorgantiCentro de Biotecnologia, Instituto de Pesquisas Energéticas e Nucleares, Comissão Nacional de Energia Nuclear, São Paulo, São Paulo, Brazil.
Elizabeth A L MartinsCentro de Biotecnologia, Instituto Butantan, São Paulo, São Paulo, Brazil.
Instituto Butantan · BRInstituto de Pesquisas Energéticas e Nucleares · BRNational Nuclear Energy Commission · BR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The prokaryotic ubiquitous Toxin-Antitoxin (TA) operons encode a stable toxin and an unstable antitoxin. The most accepted hypothesis of the physiological function of the TA system is the reversible cessation of cellular growth under stress conditions. The major TA family, VapBC is present in the spirochaete Leptospira interrogans. VapBC modules are classified based on the presence of a predicted ribonucleasic PIN domain in the VapC toxin. The expression of the leptospiral VapC in E. coli promotes a strong bacterial growth arrestment, making it difficult to express the recombinant protein. Nevertheless, we showed that long term induction of expression in E. coli enabled the recovery of VapC in inclusion bodies. The recombinant protein was successfully refolded by high hydrostatic pressure, providing a new method to obtain the toxin in a soluble and active form. The structural integrity of the recombinant VapB and VapC proteins was assessed by circular dichroism spectroscopy. Physical interaction between the VapC toxin and the VapB antitoxin was demonstrated in vivo and in vitro by pull down and ligand affinity blotting assays, respectively, thereby indicating the ultimate mechanism by which the activity of the toxin is regulated in bacteria. The predicted model of the leptospiral VapC structure closely matches the Shigella's VapC X-ray structure. In agreement, the ribonuclease activity of the leptospiral VapC was similar to the activity described for Shigella's VapC, as demonstrated by the cleavage of tRNAfMet and by the absence of unspecific activity towards E. coli rRNA. This finding suggests that the cleavage of the initiator transfer RNA may represent a common mechanism to a larger group of bacteria and potentially configures a mechanism of post-transcriptional regulation leading to the inhibition of global translation.

Indexed as

Amino Acid SequenceAnimalsAntitoxinsBacterial ProteinsBacterial ToxinsCloning, MolecularDNA-Binding ProteinsEscherichia coliGene Expression Regulation, BacterialLeptospira interrogansMembrane GlycoproteinsMice, Inbred BALB CModels, MolecularMolecular Sequence DataOperonProtein RefoldingAntitoxinsBacterial ProteinsBacterial ToxinsDNA-Binding ProteinsMembrane GlycoproteinsRecombinant ProteinsRibonucleasesRNA, Transfer, MetVapB protein, Bacteria

Identifiers

PMID25047537
PMCPMC4105405
OpenAlexW2015861584

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.